Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early minimally invasive surfactant therapy in very preterm infants on nasal respiratory support
MOH_2017-07-25_000659Phase 3Not yet recruiting
- Sponsor
- אמיר קוגלמן
- Start
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by אמיר קוגלמן. Primary endpoint: Respiratory failure reduction. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on MOH_2017-07-25_000659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-25_000659.